Valuation: Clene Inc.

Market Cap 66.32M 57.64M 53.81M 49.4M 93.15M 6.32B 94.77M 635M 249M 3.15B 249M 244M 10.4B P/E 2026 *
-2.91x
P/E 2027 * -3.53x
Enterprise Value 52.92M 45.99M 42.94M 39.42M 74.33M 5.04B 75.62M 506M 198M 2.52B 199M 194M 8.3B EV / Sales 2026 *
255x
EV / Sales 2027 * 1.9x
Free-Float
82.94%
Yield 2026 *
-
Yield 2027 * -
1 day+3.49%
1 week-4.95%
Current month+3.49%
1 month-14.92%
3 months-15.47%
6 months+21.55%
Current year-11.58%
1 week 4.63
Extreme 4.63
5.43
1 month 4.63
Extreme 4.63
6.55
Current year 3.88
Extreme 3.88
8.67
1 year 3.5
Extreme 3.5001
13.5
3 years 2.28
Extreme 2.2801
15.57
5 years 2.28
Extreme 2.2801
196.8
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 01/04/2013
Chief Tech/Sci/R&D Officer 67 01/01/2013
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Director/Board Member 78 01/03/2013
Chairman 65 19/05/2021
Director/Board Member 49 01/12/2020
Date Insider Type Main position Quantity % Market Cap.
4/5/26 Sell -72,884 0.6188%
19/2/26 Free

Director

3,168 0.0269%
19/2/26 Free

Director

3,271 0.0278%
Change 5-day change 1-year change 3-year change Capi.($)
+3.49%-4.95%+48.71%-64.01% 66.32M
+0.05%+3.08%+38.17%+66.77% 56.7B
+0.44%-6.04%+23.45%+62.06% 51.97B
+1.84%+1.27%-14.06%-13.50% 23.33B
-0.15%-6.00%-9.42%+344.47% 21.34B
+1.83%-1.26%+33.24%-25.56% 17.44B
+9.91%-2.51%+188.84%+326.19% 14.77B
+3.83%-1.34%+47.77%+165.22% 13.84B
+1.61%+0.56%+439.92%+166.12% 12.12B
+3.14%-12.56%+59.51%+149.39% 11.14B
Average +2.60%-2.59%+85.61%+117.72% 22.27B
Weighted average by Cap. +1.58%-1.95%+57.84%+109.47%

Financials

2026 *2027 *
Net sales 207K 180K 168K 154K 291K 19.77M 296K 1.98M 777K 9.86M 779K 762K 32.52M 23.64M 20.55M 19.18M 17.61M 33.21M 2.25B 33.79M 226M 88.6M 1.12B 88.81M 86.85M 3.71B
Net income -25.09M -21.81M -20.36M -18.69M -35.24M -2.39B -35.86M -240M -94.03M -1.19B -94.26M -92.17M -3.93B -27.55M -23.94M -22.35M -20.52M -38.69M -2.63B -39.37M -264M -103M -1.31B -103M -101M -4.32B
Net Debt -13.4M -11.65M -10.87M -9.98M -18.82M -1.28B -19.15M -128M -50.21M -637M -50.33M -49.22M -2.1B -21.4M -18.6M -17.36M -15.94M -30.06M -2.04B -30.58M -205M -80.19M -1.02B -80.38M -78.6M -3.36B
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
-
Date Price Change Volume
03/08/26 USD 5.190 +3.49% 27,258
31/07/26 USD 5.015 -0.50% 33,748
30/07/26 USD 5.040 +6.78% 37,350
29/07/26 USD 4.720 -5.41% 140,746
28/07/26 USD 4.990 -8.61% 93,043
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.190USD
Average target price
32.20USD
Spread / Average Target
+520.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLNN Stock